TCGA-44-2655-01A-01R-0946-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
- ADIPOGENESIS+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
- BILE_ACID_METABOLISM+0.350
- PEROXISOME+0.350
- XENOBIOTIC_METABOLISM+0.340
- COAGULATION+0.270
- TGF_BETA_SIGNALING+0.240
- P53_PATHWAY+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.620
- E2F_TARGETS-0.590
- MITOTIC_SPINDLE-0.450
- MYC_TARGETS_V2-0.450
- HEDGEHOG_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- ANGIOGENESIS-0.310
- NOTCH_SIGNALING-0.240
- HYPOXIA-0.230
- WNT_BETA_CATENIN_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.871 |
| 2 | TCGA-OR-A5J6-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.845 |
| 3 | TCGA-75-5146-01A-01R-1628-07 | — | cohortA1 | 0.831 |
| 4 | SRR8518337 | — | F | 0.825 |
| 5 | SRR4195645 | — | — | 0.816 |
| 6 | TCGA-5N-A9KM-01A-11R-A42T-07 | — | — | 0.814 |
| 7 | SRR11296843 | — | — | 0.809 |
| 8 | C3L-02549 | — | cohortA1 | 0.806 |
| 9 | SRR35579827 | — | C | 0.802 |
| 10 | dcabd821.c5d5.4a97.b657.0612d6a4439d | — | cohortA1 | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.450 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.350 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |